New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
04:55 EDTDHR, DHR, DHR, TEVA, TEVA, TEVA, GMED, GMED, GMED, RHHBY, RHHBY, RHHBY, MDCO, MDCO, MDCO, NVO, NVO, NVO, GILD, GILD, GILD, OMI, OMI, OMI, PKI, PKI, PKI, WCG, WCG, WCG, BDX, BDX, BDXGoldman to hold a conference
35th Annual Global Healthcare Conference to be held in Rancho Palos Verdes, California on June 10-12.
News For DHR;WCG;PKI;OMI;GILD;NVO;MDCO;RHHBY;GMED;TEVA;BDX From The Last 14 Days
Check below for free stories on DHR;WCG;PKI;OMI;GILD;NVO;MDCO;RHHBY;GMED;TEVA;BDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 17, 2014
17:42 EDTRHHBYCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
06:21 EDTPKIPerkinElmer initiated with a Buy at Citigroup
Target $55.
06:18 EDTDHRDanaher narrows FY14 EPS view to $3.67-$3.72, consensus $3.75
Subscribe for More Information
06:18 EDTDHRDanaher sees Q3 EPS 86c-89c, consensus 93c
Subscribe for More Information
06:04 EDTDHRDanaher reports Q2 EPS 95c, consensus 94c
Subscribe for More Information
July 16, 2014
16:05 EDTDHRDanaher to acquire Siemens Healthcare Diagnostics' clinical microbiology unit
Beckman Coulter, an indirect wholly-owned subsidiary of Danaher Corporation (DHR), announced that it has entered into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics (SIEGY). The microbiology business operates with an installed base of over 6,000 instruments globally. The transaction is expected to close in 1Q15.
15:27 EDTDHRNotable companies reporting before tomorrow's open
Subscribe for More Information
14:01 EDTDHRDanaher technical comments before earnings
Subscribe for More Information
11:57 EDTGILDStocks with call strike movement; GILD YHOO
Subscribe for More Information
11:23 EDTRHHBYRoche Alzheimer drug shows mixed results in trial, NYT says
Subscribe for More Information
08:48 EDTTEVATeva says ISS supports company's nominees, shareholders' meeting proposals
Subscribe for More Information
07:18 EDTGMEDScoliosis Research Society to hold annual meeting
Subscribe for More Information
06:26 EDTRHHBYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
11:13 EDTTEVAPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
06:28 EDTTEVAActivist shareholder says Teva to appoint new chairman, Reuters says
Subscribe for More Information
05:37 EDTRHHBYGenentech Avastin granted priority review by FDA
Subscribe for More Information
July 14, 2014
11:20 EDTRHHBYExelixis seen as potential target for Roche, TheStreet says
Subscribe for More Information
09:28 EDTGILDCentene best positioned Medicaid pure play to post Q2 EPS beat, says Sterne Agee
Subscribe for More Information
08:04 EDTTEVATeva announces FDA acceptance of NDA filing for albuterol MDPI
Teva Pharmaceuticals Industries announced that the U.S. Food and Drug Administration has accepted for review the company’s new drug application for albuterol multi-dose dry-powder inhaler, an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. The NDA filing includes data from eight clinical studies that evaluated the safety and efficacy of albuterol MDPI in adults and adolescents with asthma and exercise-induced bronchospasm. The NDA for albuterol MDPI has been accepted by the FDA for standard review, with a FDA Regulatory Action expected in March 2015.
07:20 EDTNVOControlled Released Society to hold annual meeting
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use